NCT06790303View on ClinicalTrials.gov

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

September 23, 2021

Study Completion Date

September 23, 2021

Conditions
Neoplasms
Interventions
DRUG

Feladilimab

Feladilimab will be administered.

DRUG

Ipilimumab

Ipilimumab will be administered

Trial Locations (3)

33076

GSK Investigational Site, Bordeaux

37203

GSK Investigational Site, Nashville

L6R3J7

GSK Investigational Site, Brampton

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06790303 - Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2 | Biotech Hunter | Biotech Hunter